#

Viking Therapeutics

: 12
Viking Therapeutics soared last week after the latest data for its GLP-1 therapy / Photo: Facebook/Nasdaq
Small Caps·
Motley Fool analyst calls Viking 'fantastic buy' for risk-tolerant investors
Viking has been developing its own candidate for obesity and type 2 diabetes, VK2735 / Photo: Shutterstock.com / Faizal Ramli
Small Caps·
+1
·
Viking Therapeutics soars 31% intraday on upbeat data for its obesity shot
Redwire shares have more than tripled year to date, now trading 40% above the consensus target price from Wall Street analysts / Photo: X / Redwire
Small Caps·
Small caps last week: Space stocks rally, 'GLP-1 moment for hair loss', LUNR snubbed
Before considering a purchase of this once-popular and now apparently undervalued stock, keep in mind that the company faces many hurdles in taking on competitors like Novo Nordisk and Eli Lilly, a new Motley Fool article argues / Photo: Facebook/Nasdaq
Small Caps·
Motley Fool: May be too late for dark horse role for Viking in GLP-1 wars
A Motley Fool analyst says Viking is the under-the-radar GLP-1 contender that growth hunters cant ignore / Photo: Facebook / Nasdaq
Small Caps·
Motley Fool calls Viking the GLP‑1 drugmaker growth-hunting investors 'can't ignore'
Novo impressed investors by launching a weight loss pill in the US. What are its competitors doing?
News·
Novo impressed investors by launching a weight loss pill in the US. What are its competitors doing?
Canaccord initiates on obesity drugmaker Viking with buy, sees 200% upside
Small Caps·
Canaccord initiates on obesity drugmaker Viking with 'buy,' sees 200% upside
Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market
Small Caps·
Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market
Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?
News·
Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?
Morning in New York: foreign policy agenda remains in the center of attention of the markets
News·
Morning in New York: foreign policy agenda remains in the center of attention of the markets
Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases
Small Caps·
Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases
Investors and analysts are optimistic about Viking Therapeutics weight-loss pill / Photo: Unsplash/Diana Polekhina
Small Caps·
Potential Eli Lilly and Novo Nordisk competitor surges 21% on third-quarter financials